Compare AbbVie Inc (ABBV) vs Veritone Inc (VERI) Price & Performance

ABBV trades at $247.91, up 0.76% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $3.65, beating expectations, and maintains strong profitability with a 71.48% gross margin. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer, reinforcing growth prospects beyond Humira's patent expiry.

Outlook is positive with analyst consensus target of $278.69, though high P/E of 70.05 and debt levels pose valuation and financial risks. Revenue growth driven by Skyrizi and Rinvoq offsets competitive pressures, but patent cliffs in the 2030s require monitoring. The stock offers dividend appeal with a $1.73 payout scheduled for August 2026.

Veritone (VERI) trades at $1.31, up 4.8% today, with a bullish technical signal despite negative profitability metrics. The company reported Q1 2026 revenue of $90M but missed earnings expectations with a net loss of $111M. Recent business developments include AI partnership expansions with government agencies and new redaction capabilities, while facing multiple securities class action lawsuits alleging improper revenue accounting.

Outlook remains challenging with persistent losses and negative margins, though analyst consensus shows divided sentiment with 46% buy ratings. Key risks include ongoing litigation, execution challenges in achieving profitability, and competitive pressures in the enterprise AI sector. The stock's low price presents speculative potential but requires careful risk assessment.